Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) announced on March 6, 2026 that it granted inducement awards to six new employees under its 2024 Inducement Plan.

The awards were time-based restricted stock units totaling 16,500 shares, with one-third vesting annually over three years, granted March 1, 2026 and approved under Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – NTLA

+3.35%

1 alert

+3.35% News Effect

+$48M Valuation Impact

$1.49B Market Cap

0.0x Rel. Volume

On the day this news was published, NTLA gained 3.35%, reflecting a moderate positive market reaction. This price movement added approximately $48M to the company's valuation, bringing the market cap to $1.49B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement RSUs: 16,500 shares Vesting period: 3 years Current price: $13.15 +5 more

8 metrics

Inducement RSUs 16,500 shares Aggregate RSUs granted to six new employees on March 1, 2026

Vesting period 3 years One-third of RSUs vest annually over three years

Current price $13.15 Pre-news trading level on publication date

Price change 24h -4.85% Move in the prior 24 hours before this announcement

52-week high $28.25 52-week high price prior to this news

52-week low $5.90 52-week low price prior to this news

ATM offering size $400,000,000 Common stock under 424B5 at-the-market program with Jefferies

ATM commission 3.0% Commission on gross proceeds to Jefferies as sales agent

Market Reality Check

Price: $12.76 Vol: Volume 4,277,963 is rough...

normal vol

$12.76 Last Close

Volume Volume 4,277,963 is roughly in line with 20-day average 4,233,441 (relative volume 1.01). normal

Technical Shares at $13.15 are trading above the 200-day moving average of $12.33, while sitting 53.45% below the 52-week high and 122.88% above the 52-week low.

Peers on Argus

NTLA fell 4.85% while close peers were mixed: DNTH up 0.87%, ELVN down 2.14%, RC...

NTLA fell 4.85% while close peers were mixed: DNTH up 0.87%, ELVN down 2.14%, RCUS down 0.8%, TRML flat, ZYME down 0.72%. Moves do not indicate a coordinated sector rotation.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Clinical data update	Positive	-11.9%	Longer-term Phase 1/2 lonvo-z HAE data with durable attack reduction.
Mar 02	Regulatory trial update	Positive	+12.1%	FDA lifted clinical hold on MAGNITUDE Phase 3 ATTR-CM trial.
Feb 26	Earnings and pipeline	Positive	+6.4%	Q4/FY 2025 results, cash of <b>$605.1M</b>, and HAELO Phase 3 timeline.
Feb 24	Investor conferences	Neutral	+3.2%	Participation in multiple March 2026 healthcare investor conferences.
Feb 19	Earnings call notice	Neutral	+4.5%	Scheduled call to discuss Q4 and full-year 2025 results and updates.

Pattern Detected

Recent news has mostly seen price gains on program and earnings updates, with one notable selloff on positive clinical data.

Recent Company History

Over the past few weeks, Intellia has reported several key milestones. On Feb 26, Q4 and full-year 2025 results highlighted $605.1M in cash and plans for HAELO Phase 3 topline data by mid-2026, with a 6.41% gain. The FDA’s lift of the MAGNITUDE Phase 3 hold on Mar 02 drove a 12.05% rise. By contrast, longer-term lonvo-z HAE data on Mar 03 was followed by an 11.88% decline. The current inducement-grant announcement fits into an active period of clinical and financing updates.

Market Pulse Summary

This announcement details inducement equity grants of 16,500 RSUs to six new employees, vesting over...

Analysis

This announcement details inducement equity grants of 16,500 RSUs to six new employees, vesting over 3 years under Nasdaq Listing Rule 5635(c)(4). It follows a busy period that included a lifted FDA hold on MAGNITUDE, strong lonvo-z HAE data, and an at-the-market offering of up to $400,000,000. Investors may watch how ongoing trial milestones, cash usage, and additional equity issuance interact with existing volatility and prior reactions to clinical updates.

Key Terms

restricted stock units, RSUs, Nasdaq Listing Rule 5635(c)(4), equity incentive plans

4 terms

restricted stock units financial

"The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"time-based restricted stock units (“RSUs”) for an aggregate of 16,500 shares of Intellia’s common stock..."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Nasdaq Listing Rule 5635(c)(4) regulatory

"awards were approved... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity incentive plans financial

"awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant..."

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on March 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 16,500 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Contact:

Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

FAQ

What did Intellia (NTLA) announce on March 6, 2026 about inducement grants?

Intellia announced inducement awards to six new employees totaling 16,500 RSUs. According to the company, the awards were granted March 1, 2026 under the 2024 Inducement Plan and approved by the compensation committee as a material inducement to employment.

How many shares and what vesting schedule did NTLA grant in the inducement awards?

Intellia granted an aggregate of 16,500 time-based RSUs with one-third vesting annually over three years. According to the company, vesting is subject to continued service through each applicable vesting date and the awards were granted outside stockholder-approved plans.

Were the NTLA inducement grants approved under Nasdaq rules and why?

Yes, the compensation committee approved the awards as a material inducement under Nasdaq Listing Rule 5635(c)(4). According to the company, that approval authorized grants outside of existing stockholder-approved equity incentive plans pursuant to the 2024 Inducement Plan.

Who received the inducement grants from Intellia (NTLA) and under which plan were they issued?

Six new employees received the inducement awards under Intellia’s 2024 Inducement Plan. According to the company, the awards were issued outside its stockholder-approved equity incentive plans and adopted by the board in June 2024.

Do the 16,500 RSUs from NTLA immediately vest or affect shareholder voting rights?

The RSUs do not immediately vest; one-third vests annually over three years and vesting requires continued service. According to the company, these are time-based RSUs and vesting is subject to employment or service through each vesting date.